2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists

Dong-Mei Feng; Jenny M Wai; Scott D Kuduk; Christina Ng; Kathy L Murphy; Richard W Ransom; Duane Reiss; Raymond S L Chang; Charles M Harrell; Tanya MacNeil; Cuyue Tang; Thomayant Prueksaritanont; Roger M Freidinger; Douglas J Pettibone; Mark G Bock

doi:10.1016/j.bmcl.2005.02.077

2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists

Bioorg Med Chem Lett. 2005 May 2;15(9):2385-8. doi: 10.1016/j.bmcl.2005.02.077.

Authors

Dong-Mei Feng¹, Jenny M Wai, Scott D Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Duane Reiss, Raymond S L Chang, Charles M Harrell, Tanya MacNeil, Cuyue Tang, Thomayant Prueksaritanont, Roger M Freidinger, Douglas J Pettibone, Mark G Bock

Affiliation

¹ Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. dongmei_feng@merck.com

PMID: 15837330
DOI: 10.1016/j.bmcl.2005.02.077

Abstract

A novel class of 2,3-diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure-activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.

MeSH terms

Aminopyridines / chemistry
Aminopyridines / pharmacology*
Bradykinin B1 Receptor Antagonists*
Drug Design
Humans
Kinetics
Models, Molecular
Pyridines / chemical synthesis*
Pyridines / pharmacology
Structure-Activity Relationship

Substances

Aminopyridines
Bradykinin B1 Receptor Antagonists
Pyridines
2,3-diaminopyridine